Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSH2 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
GSH2 small interfering RNA is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of the GS Homeobox 2 (GSH2, also known as GSX2) gene. GSH2 is a transcription factor that is frequently overexpressed in pancreatic ductal adenocarcinoma (PDAC) and is associated with tumor progression and resistance to chemotherapy, particularly gemcitabine. By utilizing the RNA interference pathway to degrade GSH2 mRNA, this agent reduces GSH2 protein levels. Preclinical studies in cell cultures and xenograft mouse models have demonstrated that silencing GSH2 inhibits cancer cell proliferation, migration, and invasion while promoting apoptosis. Furthermore, GSH2 silencing has been shown to alleviate gemcitabine resistance, a process mediated by the activation of the Sonic hedgehog (SHH)/GLI1 signaling pathway.
- Other names
- GSX2 small interfering RNAGSX-2 small interfering RNAGSX 2 small interfering RNAsi-GSH2si-GSH-2si-GSH 2si-GSX2si-GSX-2si-GSX 2
Beyond the preview
Go deeper on GSH2 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSH2 small interfering RNA.